Yubo International Biotech Limited
Yubo International Biotech Limited (YBGJ) Revenue
Annual & quarterly revenue history · segment & region breakdown
YBGJ · revenue · updated Jun 15, 2026
Core revenue metrics
Trailing 12 monthsYubo International Biotech Limited trailing twelve-month (TTM) revenue is $0.00B, an increase of 3772.94% year-over-year from $0.00B in FY2025.
Revenue trend
2025 – 2005 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.00B | +$0.00B | +3772.94% |
| 2024-12-31 | $0.00B | -$0.00B | -96.67% |
| 2022-12-31 | $0.00B | -$0.00B | -91.62% |
| 2021-12-31 | $0.00B | -$0.00B | -8.09% |
| 2020-12-31 | $0.00B | +$0.00B | — |
| 2019-02-28 | $0.00B | +$0.00B | — |
| 2018-02-28 | $0.00B | +$0.00B | — |
| 2017-02-28 | $0.00B | +$0.00B | — |
| 2016-02-29 | $0.00B | +$0.00B | — |
| 2015-02-28 | $0.00B | -$0.00B | -100.00% |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Yubo International Biotech Limited receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Yubo International Biotech Limited reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Yubo International Biotech Limited's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
YBGJ revenue · 4 questionsYBGJ's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 3772.94% year-over-year from $0.00B in FY2025.
▸ Source: FMP · Yubo International Biotech Limited SEC filings · GAAP · Yubo International Biotech Limited SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 15, 2026